We are focused on the development and commercialisation of clinical-stage oncology programs.
Telix Pharmaceuticals is focused on the development and commercialisation of several clinical-stage oncology assets in renal cancer, prostate cancer and brain cancer.
We are also actively exploring indication expansion opportunities for our programs and platforms as they reflect diagnostic and therapeutic approaches that may be relevant to other important clinical applications.
TLX250 targets clear cell renal cell cancer, the most common and aggressive form of kidney cancer.
Prostate cancer is a major killer of men and is the most commonly diagnosed cancer in males.